Dossier assessment
Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma and tumour PD-L1 expression with a TAP (Tumour Area Positivity) score ≥ 5%, and
- tumour PD-L1 expression ≥ 1 (combined positive score; CPS) for first-line treatment: added benefit not proven
- tumour PD-L1 expression < 1 (combined positive score; CPS) for first-line treatment: added benefit not proven
Project details
- Project no.
- A24-131
- Commission
- Commission awarded on 20.12.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-131_en
Connected Projects
-
Dossier assessment
Tislelizumab (oesophageal carcinoma, advanced, second line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (non-squamous NSCLC) - Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (squamous NSCLC, first line) – Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (NSCLC, second line) - Benefit assessment according to § 35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (nasopharyngeal carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Tislelizumab (small cell lung cancer, extensive stage) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed